|
[1] von HAHN T,CIESEK S,WEGENER G,et al. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany[J]. Scand J Gastroenterol,2011,46(9):1092-1098.
|
|
[2] RAOOF M,SINGH G. Rising trends in intrahepatic cholangiocarcinoma incidence and mortality:Getting at the root cause[J]. Hepatobiliary Surg Nutr,2019,8(3):301-303.
|
|
[3] Liver Cancer Study Group of Japan. Primary liver cancer in Japan clinicopathologic features and results of surgical treatment[J]. Ann Surg,1990,211(3):277-287.
|
|
[4] CHEN JJ,LI WG. An excerpt of(2016)cholangiocarcinoma:Current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma(ENS-CCA)[J]. J Clin Hepatol,2016,32(10):1847-1850.(in Chinese)陈嘉佳，李文岗．《2016年欧洲胆管癌研究网络共识:胆管细胞癌研究现状及前景展望》摘译[J]．临床肝胆病杂志，2016,32(10):1847-1850.
|
|
[5] SAHA SK,ZHU AX,FUCHS CS,et al. Forty-year trends in cholangiocarcinoma incidence in the U. S.:Intrahepatic disease on the rise[J]. Oncologist,2016,21(5):594-599.
|
|
[6] BRIDGEWATER J,GALLE PR,KHAN SA,et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol,2014,60(6):1268-1289.
|
|
[7] PENG NF,LI LQ,QIN X,et al. Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China:A possible role of hepatitis B virus[J]. Ann Surg Oncol,2011,18(5):1258-1266.
|
|
[8] GRAINGE MJ,WEST J,SOLAYMANI-DODARAN M,et al.The antecedents of biliary cancer:A primary care case-control study in the United Kingdom[J]. Br J Cancer,2009,100(1):178-180.
|
|
[9] SEMPOUX C,JIBARA G,WARD SC,et al. Intrahepatic cholangiocarcinoma:New insights in pathology[J]. Semin Liver Dis,2011,31(1):49-60.
|
|
[10] ZHANG XF,CHAKEDIS J,BAGANTE F,et al. Trends in use of lymphadenectomy in surgery with curative intent for intrahepatic cholangiocarcinoma[J]. Br J Surg,2018,105(7):857-866.
|
|
[11] RUZZENENTE A,CONCI S,VIGANL,et al. Role of lymph node dissection in small(≤3 cm)intrahepatic cholangiocarcinoma[J]. J Gastrointest Surg,2019,23(6):1122-1129.
|
|
[12] ARIIZUMI S,KOTERA Y,KATAGIRI S,et al. Long-term survival of patients with cholangiolocellular carcinoma after curative hepatectomy[J]. Ann Surg Oncol,2014,21 Suppl 3:s451-s458.
|
|
[13] TANG ZH,QUAN ZW. Surgical and comprehensive treatment for intrahepatic cholangiocarcinoma patients from the perspective of tumor heterogeneity[J]. Chin J Surg,2018,56(5):328-331.(in Chinese)汤朝晖，全志伟．从肿瘤异质性看肝内胆管细胞癌外科及综合治疗的策略选择[J]．中华外科杂志，2018,56(5):328-331.
|
|
[14] SEEHAWER M,HEINZMANN F,D’ARTISTA L,et al. Necroptosis microenvironment directs lineage commitment in liver cancer[J]. Nature,2018,562(7725):69-75.
|
|
[15] SIA D,HOSHIDA Y,VILLANUEVA A,et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes[J]. Gastroenterology,2013,144(4):829-840.
|
|
[16] ZOU S,LI J,ZHOU H,et al. Mutational landscape of intrahepatic cholangiocarcinoma[J]. Nat Commun,2014,5:5696.
|
|
[17] GOYAL L,GOVINDAN A,SHETH RA,et al. Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase(IDH)mutant and IDH wild-type intrahepatic cholangiocarcinoma[J]. Oncologist,2015,20(9):1019-1027.
|
|
[18] SINGH S,TANG SJ,SREENARASIMHAIAH J,et al. The clinical utility and limitations of serum carbohydrate antigen(CA19-9)as a diagnostic tool for pancreatic cancer and cholangiocarcinoma[J]. Dig Dis Sci,2011,56(8):2491-2496.
|
|
[19] XU HX,CHEN LD,LIU LN,et al. Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma:Correlation with pathological examination[J]. Br J Radiol,2012,85(1016):1029-1037.
|
|
[20] VALLS C,GUMA,PUIG I,et al. Intrahepatic peripheral cholangiocarcinoma:CT evaluation[J]. Abdom Imaging,2000,25(5):490-496.
|
|
[21] ZHAO YJ,CHEN WX,WU DS,et al. Differentiation of massforming intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma:Based on the multivariate analysis of contrast-enhanced computed tomography findings[J]. Abdom Radiol(NY),2016,41(5):978-989.
|
|
[22] KIM SA,LEE JM,LEE KB,et al. Intrahepatic mass-forming cholangiocarcinomas:Enhancement patterns at multiphasic CT,with special emphasis on arterial enhancement pattern—correlation with clinicopathologic findings[J]. Radiology,2011,260(1):148-157.
|
|
[23] YONG EC,KIM MJ,PARK YN,et al. Varying appearances of cholangiocarcinoma radiologicpathologic correlation[J]. Radio Graphics,2009,29(3):683-700.
|
|
[24] YOSHIMITSU K. Differentiation of two subtypes of intrahepatic cholangiocarcinoma:Imaging approach[J]. Eur Radiol,2019,29(6):3108-3110.
|
|
[25] JIANG L,TAN H,PANJE CM,et al. Role of 18F-FDG PET/CT imaging in intrahepatic cholangiocarcinoma[J]. Clin Nucl Med,2016,41(1):1-7.
|
|
[26] OKABAYASHI T,YAMAMOTO J,KOSUGE T,et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma:Analysis of preoperative and postoperative variables[J]. Cancer,2001,92(9):2374-2383.
|
|
[27] YAMASAKI S. Intrahepatic cholangiocarcinoma:Macroscopic type and stage classification[J]. J Hepatobiliary Pancreat Surg,2003,10(4):288-291.
|
|
[28] NATHAN H,ALOIA TA,VAUTHEY JN,et al. A proposed staging system for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol,2009,16(1):14-22.
|
|
[29] MENG ZW,PAN W,HONG HJ,et al. Macroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC/UICC TNM staging system[J]. Oncotarget,2017,8(60):101165-101174.
|
|
[30] WANG Y,LI J,XIA Y,et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy[J]. J Clin Oncol,2013,31(9):1188-1195.
|
|
[31] WEBER SM,RIBERO D,O’REILLY EM,et al. Intrahepatic cholangiocarcinoma:Expert consensus statement[J]. HPB(Oxford),2015,17(8):669-680.
|
|
[32] STOCKMANN M,BEDNARSCH J,MALINOWSKI M,et al. Functional considerations in ALPPS-consequences for clinical management[J]. HPB(Oxford),2017,19(11):1016-1025.
|
|
[33] ZHANG XF,BEAL EW,BAGANTE F,et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent[J]. Br J Surg,2018,105(7):848-856.
|
|
[34] BERGEAT D,SULPICE L,RAYAR M,et al. Extended liver resections for intrahepatic cholangiocarcinoma:Friend or foe?[J]. Surgery,2015,157(4):656-665.
|
|
[35] HOYOS S,NAVAS MC,RESTREPO JC,et al. Current controversies in cholangiocarcinoma[J]. Biochim Biophys Acta Mol Basis Dis,2018,1864(4 Pt B):1461-1467.
|
|
[36] SHEN F,ZHANG H,YANG T,et al. The comprehensive surgical management for intrahepatic cholangiocarcinoma[J].Chin J Dig Surg,2018,17(3):213-218.(in Chinese)沈锋，张汉，杨田，等．肝内胆管癌的外科综合治疗[J]．中华消化外科杂志，2018,17(3):213-218.
|
|
[37] LI DY,ZHANG HB,YANG N,et al. Routine lymph node dissection may be not suitable for all intrahepatic cholangiocarcinoma patients:Results of a monocentric series[J]. World J Gastroenterol,2013,19(47):9084-9091.
|
|
[38] AMINI N,EJAZ A,SPOLVERATO G,et al. Management of lymph nodes during resection of hepatocellular carcinoma and intrahepatic cholangiocarcinoma:A systematic review[J]. J Gastrointest Surg,2014,18(12):2136-2148.
|
|
[39] MORINE Y,SHIMADA M. The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics[J]. J Gastroenterol,2015,50(9):913-927.
|
|
[40] CHEN YX,ZENG ZC,TANG ZY,et al. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma:A retrospective analysis of 84 patients[J]. BMC Cancer,2010,10:492.
|
|
[41] VALLE JW,WASAN H,JOHNSON P,et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours:A multicentre randomised phase II study-The UK ABC-01 Study[J].Br J Cancer,2009,101(4):621-627.
|
|
[42] ABDEL-RAHMAN O,ELSAYED Z,ELHALAWANI H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas[J]. Cochrane Database Syst Rev, 2018, 4:CD011746.
|
|
[43] GOYAL L,SAHA SK,LIU LY,et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma[J].Cancer Discov,2017,7(3):252-263.
|
|
[44] TARIQ NU,MCNAMARA MG,VALLE JW. Biliary tract cancers:Current knowledge,clinical candidates and future challenges[J]. Cancer Manag Res,2019,11:2623-2642.
|
DownLoad: